<DOC>
	<DOCNO>NCT01091142</DOCNO>
	<brief_summary>Primary objective : To assess safety tolerability ascend dos NP001 compare placebo subject ALS . Secondary objective : To explore effect NP001 biomarkers potentially relevant ALS .</brief_summary>
	<brief_title>Single-Ascending-Dose Safety/Tolerability NP001 Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This study double-blind , placebo-controlled single ascend dose safety tolerability study . Approximately 32-56 subject clinical diagnosis ALS accord modify El Escorial criterion plan receive single dose study drug , NP001 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Males female , age 21 year 75 year Subjects must generally sound health appropriate ALS diagnosis . Subjects must clinical diagnosis laboratorysupported probable definite ALS , accord modify El Escorial criterion . Subjects receive riluzole must stable dose least 30 day prior enrollment . Women childbearing age must nonlactating surgically sterile use effective method birth control negative pregnancy test prior dose study medication . Subjects must understand study willing adhere protocol requirement evidence provision write informed consent . Subject must willing able give sign informed consent approve Institutional Review Board ( IRB ) . Subjects must willing intravenous infusion . Subjects must suitable vein IV access determine examination . Subjects require expect require life sustain intervention next six month longer . ( e.g . invasive ventilation ) . Subjects must : presence tracheotomy invasive ventilation . Nocturnal noninvasive ventilation system ( e.g . CPAP ) allow . diagnosis neurologic disease know mimic muscle atrophy weakness see ALS include MS , muscular dystrophy , spinal stenosis , peripheral neuropathy , inherited neuropathy neuromuscular disease , foramen magnum brainstem tumor , toxic condition . active pulmonary disease treatment include uncontrolled asthma , chronic obstructive pulmonary disease ( pneumonia , bronchitis , etc . ) , pulmonary fibrosis , pulmonary infection last 2 month , history aspiration may expose subject increase risk participate trial determine Investigator . history unstable medical illness 3 month prior screen include emergent hospitalization . renal disease base screening estimate creatinine clearance ( eCcr ) &lt; 50 mL/minute ( Cockcroft Gault estimate use ideal body weight ) : evidence elevate alanine aminotransferase great 3 time upper limit normal . evidence anemia , thrombocytopenia , neutropenia ( screen hematocrit &lt; 33 % , platelet count &lt; low limit normal site laboratory , neutrophil count le 1,500/mm3 ) . condition require periodic red blood cell transfusion , erythropoietin blood dyscrasia undergo active treatment past year . clinical laboratory parameter clinically significant opinion Investigator . systolic blood pressure excess 160 mmHg less 100 mmHG diastolic blood pressure 98 mmHg . history G6PD deficiency ( Glucose6phosphate dehydrogenase deficiency ) determine subject report . current history hepatitis HIV determine subject report . Subjects must use systemic immunosuppressant include steroid chemotherapeutic agent . Inhaled steroid , eye drop local topical use permit concurrence Medical Monitor . Subjects must hematologic disorder autoimmune anemia , hemolytic anemia type include paroxysmal nocturnal hemoglobinuria myoglobinuria . Subjects must history unexplained jaundice determine subject report . Subjects must receive IV Immunoglobulin ( IG ) within 30 day plan initial dose study drug . Subjects must participate another drug study participate drug study within last 30 day prior enrollment . Observational trial intervention acceptable provide permission study Sponsor obtain write . Subjects must condition Investigator 's opinion would put subject risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>